KPTI · Karyopharm Therapeutics Inc.
$0.69
-0.11 (-13.66%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$36.74M
Shares
22.68M
Volume · Oct 5
634.29K
Avg daily vol (3M)
1.66M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.80
Open$0.86
Day$0.75–0.89
52W close$0.80–10.67
Avg vol 30d1.4M
Short int7.9M · 34.7% float · 5.0d
Short vol53%
Last earningsAug 13, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Oct 23, 2026
Est · unconfirmed
· in 3 wks
filed Aug 13, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$146.62M
Trailing 12 months
Net income (TTM)
−$224.74M
Trailing 12 months
Revenue growth YoY
-11.9%
Year over year
Operating margin
-56.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+235.7%
Year over year · more shares
Price change (1Y)
-87.2%
Trailing year
Short interest
34.7%
Latest settlement · 5.0 days to cover
AI Brief
Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26
TL;DR. Karyopharm remains on track to submit its sNDA in August seeking accelerated approval of selinexor plus ruxolitinib in myelofibrosis, while reaffirming its 2026 revenue guidance; however, the XPORT-EC-042 Phase 3 in endometrial cancer failed to meet its primary endpoint, and the company warned that without additional financing or a lender waiver, a $15.8 million September 10 payment would push liquidity below its $10 million covenant and trigger a default.
Bullish
- + Company remains on track to submit sNDA in August for selinexor plus ruxolitinib in myelofibrosis under accelerated approval, with FDA written feedback that SVR35 appears to qualify as a reasonably likely surrogate endpoint.
- + SVR35 responses with the selinexor plus ruxolitinib combination were nearly double those of ruxolitinib alone at week 24 and were rapid, deep, and sustained through week 36.
- + Phase 3 SENTRY overall survival hazard ratio was 0.43 and SVR35 was shown to predict overall survival, supporting the regulatory package.
- + U.S. XPOVIO net product revenue rose to $30.8 million in Q2 2026 from $29.7 million in Q2 2025, and R&D and SG&A expenses declined year over year.
Bearish
- − Cash runway only extends into September 2026, and a $15.8 million term loan payment due September 10, 2026 without additional financing or a lender waiver would push liquidity below the $10 million minimum covenant and trigger an event of default.
- − Q2 2026 net loss widened to $67.0 million from $37.3 million in the prior-year period, driven primarily by $32.1 million of non-cash other expense from mark-to-market adjustments.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−88%
below
Price vs 50-day avg
−65%
below
RSI (14)
19
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−55%
trailing
6-month return
−90%
trailing
YTD return
−89%
this year
Relative strength
−102%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+19% holders QoQ · +33 funds added
Insider flow
Distributing
Net -$1.8K over 90 days · 100% sells
Short interest
Falling
34.68% of float · ▼ -19.9% MoM · 5.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
100 holders — mid 3-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
+1%
Y/Y
EPS growth
−28%
Y/Y
Free cash flow
$-75.4M
Balance sheet
$21.2M
net cash
Quant / Vol
risk profile
Volatility
116%
annualized · 1-yr
Max drawdown
−92%
past year
ATR
27.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 13, 2026
Total revenue
· full year 2026
Initiated
$130M – $150M
prior FY $146.07M
midpoint −4.2% Y/Y
U.S. XPOVIO net product revenue
· full year 2026
Initiated
$115M – $130M
R&D and selling, general and administrative (SG&A) expenses
· full year 2026
Initiated
$230M – $245M
Guided vs delivered
· last 2 settled
Total revenue
full year 2024
guided $145M – $160M
$145.24M
In line
Total revenue
full year 2023
guided $145M – $160M
$146.03M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−88%
Bearish
Price vs 50-day avg
−65%
Bearish
RSI (14)
19
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+19% holders QoQ · +33 funds added
Insider flow
Distributing
Net -$1.8K over 90 days · 100% sells
Short interest
Falling
34.68% of float · ▼ -19.9% MoM · 5.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
100 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $11
vs 200-day avg -88%
vs 50-day avg -65%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Total license and other revenue | 2.66M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KPTI
this stock
Karyopharm Therapeutics Inc.
|
$36.74M | -89.1% | +0.6% | — | 34.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KPTI | -50.5% | -54.7% | -90.3% | -34.3% | -89.1% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -50.3% | -54.2% | -102.5% | -35.2% | -102.0% |